Skip to main content

Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate.

Publication ,  Journal Article
Prates, PRL; Williams, JB; Mehta, RH; Stevens, SR; Thomas, L; Smith, PK; Newby, LK; Kalil, RAK; Alexander, JH; Lopes, RD
Published in: Braz J Cardiovasc Surg
April 2016

INTRODUCTION: Antiplatelet therapy after coronary artery bypass graft (CABG) has been used. Little is known about the predictors and efficacy of clopidogrel in this scenario. OBJECTIVE: Identify predictors of clopidogrel following CABG. METHODS: We evaluated 5404 patients who underwent CABG between 2000 and 2009 at Duke University Medical Center. We excluded patients undergoing concomitant valve surgery, those who had postoperative bleeding or death before discharge. Postoperative clopidogrel was left to the discretion of the attending physician. Adjusted risk for 1-year mortality was compared between patients receiving and not receiving clopidogrel during hospitalization after undergoing CABG. RESULTS: At hospital discharge, 931 (17.2%) patients were receiving clopidogrel. Comparing patients not receiving clopidogrel at discharge, users had more comorbidities, including hyperlipidemia, hypertension, heart failure, peripheral arterial disease and cerebrovascular disease. Patients who received aspirin during hospitalization were less likely to receive clopidogrel at discharge (P≤0.0001). Clopidogrel was associated with similar 1-year mortality compared with those who did not use clopidogrel (4.4% vs. 4.5%, P=0.72). There was, however, an interaction between the use of cardiopulmonary bypass and clopidogrel, with lower 1-year mortality in patients undergoing off-pump CABG who received clopidogrel, but not those undergoing conventional CABG (2.6% vs 5.6%, P Interaction = 0.032). CONCLUSION: Clopidogrel was used in nearly one-fifth of patients after CABG. Its use was not associated with lower mortality after 1 year in general, but lower mortality rate in those undergoing off-pump CABG. Randomized clinical trials are needed to determine the benefit of routine use of clopidogrel in CABG.

Duke Scholars

Published In

Braz J Cardiovasc Surg

DOI

EISSN

1678-9741

Publication Date

April 2016

Volume

31

Issue

2

Start / End Page

106 / 114

Location

Brazil

Related Subject Headings

  • Ticlopidine
  • Survival Rate
  • Prognosis
  • Prevalence
  • Postoperative Period
  • Postoperative Complications
  • Postoperative Care
  • Platelet Aggregation Inhibitors
  • Patient Discharge
  • North Carolina
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Prates, P. R. L., Williams, J. B., Mehta, R. H., Stevens, S. R., Thomas, L., Smith, P. K., … Lopes, R. D. (2016). Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. Braz J Cardiovasc Surg, 31(2), 106–114. https://doi.org/10.5935/1678-9741.20160019
Prates, Paulo Roberto L., Judson B. Williams, Rajendra H. Mehta, Susanna R. Stevens, Laine Thomas, Peter K. Smith, L Kristin Newby, Renato A. K. Kalil, John H. Alexander, and Renato D. Lopes. “Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate.Braz J Cardiovasc Surg 31, no. 2 (April 2016): 106–14. https://doi.org/10.5935/1678-9741.20160019.
Prates PRL, Williams JB, Mehta RH, Stevens SR, Thomas L, Smith PK, et al. Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. Braz J Cardiovasc Surg. 2016 Apr;31(2):106–14.
Prates, Paulo Roberto L., et al. “Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate.Braz J Cardiovasc Surg, vol. 31, no. 2, Apr. 2016, pp. 106–14. Pubmed, doi:10.5935/1678-9741.20160019.
Prates PRL, Williams JB, Mehta RH, Stevens SR, Thomas L, Smith PK, Newby LK, Kalil RAK, Alexander JH, Lopes RD. Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. Braz J Cardiovasc Surg. 2016 Apr;31(2):106–114.

Published In

Braz J Cardiovasc Surg

DOI

EISSN

1678-9741

Publication Date

April 2016

Volume

31

Issue

2

Start / End Page

106 / 114

Location

Brazil

Related Subject Headings

  • Ticlopidine
  • Survival Rate
  • Prognosis
  • Prevalence
  • Postoperative Period
  • Postoperative Complications
  • Postoperative Care
  • Platelet Aggregation Inhibitors
  • Patient Discharge
  • North Carolina